At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 208 enrolled
Drug / intervention
BIC/FTC/TAFdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)
In Brief
A Phase 4 clinical trial evaluating BIC/FTC/TAF for HIV Infections. Completed, enrolled 208 participants across 15 sites.
Detailed Summary
The goal of this study is to analyze in treatment-naïve HIV patients the antiviral activity, using a test and treat strategy, in real life of BIC/FTC/TAF. Secondary, this study aims to evaluate outcomes for implementation of the evidence based test and treat strategy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesSpain
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
202120222023202420252026
Enrollment StartOct 2020
Primary CompletionOct 2023
First PostedDec 2023
TodayJul 2026
First PostedDec 20, 2023
Enrollment StartOct 27, 2020
Primary CompletionOct 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 2.5 years ago
Interventions
BIC/FTC/TAFdrug
TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.